|
|
|
|
|
|
|
Influenza, or as it is commonly known, the flu, is
a contagious respiratory disease caused by a virus.
The influenza virus can cause mild to severe illness, and while most people
recover without complications in 1-2 weeks, the disease at times can lead to death.
The best approach to influenza is through prevention but once the infection
takes place and the symptoms appear (high fever, headache, extreme tiredness etc)
the disease needs to be treated.
Today serious concern is caused by two particular forms of influenza called
Avian influenza (bird flu). and Swine influenza (swine flu).
|
|
|
| A Georgetown University Medical Center professor says the voluntary action taken by two research teams to temporarily halt work involving the highly pathogenic avian influenza H5N1 is "laudable... ... more info |
| On Thursday the Vietnamese authorities reported that a duck farmer has died of bird flu, coinciding with reports that a two-year-old boy in Cambodia has also died of the virus this week. The Vietnamese victim died on 11 January. According to the authorities this was the first human death from avian flu for nearly two years... ... more info |
| US scientists propose that flu pandemics follow La Niña weather conditions in the equatorial Pacific. The conditions alter bird migration patterns and this promotes new strains of flu (migrating birds are known to be primary pools of human influenza virus)... ... more info |
| The Hong Kong Centre for Health Protection (CHP) received notification from the Ministry of Health (MoH) on the 30th December concerning a suspected human case of influenza A (H5N1) in Shenzhen. The man has unfortunately died... ... more info |
| Authorities in Hong Kong have banned imports of poultry products from certain places in neighbouring Shenzhen, a major city in the south of Southern China's Guangdong Province, following the death there of a man confirmed as having the deadly form of bird flu known as highly pathogenic avian influenza (HPAI) H5N1... ... more info |
|
| "Scientists have developed genetically modified [GM] chickens that don't transmit bird flu [H5N1] to other chickens," HealthDay News/Bloomberg Businessweek reports... ... more info |
| Chickens genetically modified to prevent them spreading bird flu have been produced by researchers at the Universities of Cambridge and Edinburgh. The scientists have successfully developed genetically modified (transgenic) chickens that do not transmit avian influenza virus to other chickens with which they are in contact... ... more info |
| A genetically modified chicken that does not pass on avian influenza (bird flu) to other chickens, effectively protecting the health of domestic poultry has been developed by scientists at the Roslin Institute and Cambridge University, UK. The Roslin Institute is part of the University of Edinburgh... ... more info |
| On Thursday the Vietnamese authorities reported that a duck farmer has died of bird flu, coinciding with reports that a two-year-old boy in Cambodia has also died of the virus this week. The Vietnamese victim died on 11 January. According to the authorities this was the first human death from avian flu for nearly two years... ... more info |
| Two academic groups agreed a halt for 60 days on further work ahead of international debate on ethical and practical issues ... more info |
| On Thursday the Vietnamese authorities reported that a duck farmer has died of bird flu, coinciding with reports that a two-year-old boy in Cambodia has also died of the virus this week. The Vietnamese victim died on 11 January. According to the authorities this was the first human death from avian flu for nearly two years... ... more info |
| On Thursday the Vietnamese authorities reported that a duck farmer has died of bird flu, coinciding with reports that a two-year-old boy in Cambodia has also died of the virus this week. The Vietnamese victim died on 11 January. According to the authorities this was the first human death from avian flu for nearly two years... ... more info |
| US scientists propose that flu pandemics follow La Niña weather conditions in the equatorial Pacific. The conditions alter bird migration patterns and this promotes new strains of flu (migrating birds are known to be primary pools of human influenza virus)... ... more info |
| The Hong Kong Centre for Health Protection (CHP) received notification from the Ministry of Health (MoH) on the 30th December concerning a suspected human case of influenza A (H5N1) in Shenzhen. The man has unfortunately died... ... more info |
| Authorities in Hong Kong have banned imports of poultry products from certain places in neighbouring Shenzhen, a major city in the south of Southern China's Guangdong Province, following the death there of a man confirmed as having the deadly form of bird flu known as highly pathogenic avian influenza (HPAI) H5N1... ... more info |
|
| "Scientists have developed genetically modified [GM] chickens that don't transmit bird flu [H5N1] to other chickens," HealthDay News/Bloomberg Businessweek reports... ... more info |
| Chickens genetically modified to prevent them spreading bird flu have been produced by researchers at the Universities of Cambridge and Edinburgh. The scientists have successfully developed genetically modified (transgenic) chickens that do not transmit avian influenza virus to other chickens with which they are in contact... ... more info |
| A genetically modified chicken that does not pass on avian influenza (bird flu) to other chickens, effectively protecting the health of domestic poultry has been developed by scientists at the Roslin Institute and Cambridge University, UK. The Roslin Institute is part of the University of Edinburgh... ... more info |
| US scientists propose that flu pandemics follow La Niña weather conditions in the equatorial Pacific. The conditions alter bird migration patterns and this promotes new strains of flu (migrating birds are known to be primary pools of human influenza virus)... ... more info |
| The Hong Kong Centre for Health Protection (CHP) received notification from the Ministry of Health (MoH) on the 30th December concerning a suspected human case of influenza A (H5N1) in Shenzhen. The man has unfortunately died... ... more info |
| Authorities in Hong Kong have banned imports of poultry products from certain places in neighbouring Shenzhen, a major city in the south of Southern China's Guangdong Province, following the death there of a man confirmed as having the deadly form of bird flu known as highly pathogenic avian influenza (HPAI) H5N1... ... more info |
|
| "Scientists have developed genetically modified [GM] chickens that don't transmit bird flu [H5N1] to other chickens," HealthDay News/Bloomberg Businessweek reports... ... more info |
| Chickens genetically modified to prevent them spreading bird flu have been produced by researchers at the Universities of Cambridge and Edinburgh. The scientists have successfully developed genetically modified (transgenic) chickens that do not transmit avian influenza virus to other chickens with which they are in contact... ... more info |
| A genetically modified chicken that does not pass on avian influenza (bird flu) to other chickens, effectively protecting the health of domestic poultry has been developed by scientists at the Roslin Institute and Cambridge University, UK. The Roslin Institute is part of the University of Edinburgh... ... more info |
| Man in China dies of avian flu just days after Hong Kong slaughters thousands of chickens ... more info |
| A 39-year-old man in southern China died Saturday from what appears to be a contagious strain of avian flu, state media reported Saturday. ... more info |
| A 39-year-old man is in a southern Chinese hospital suffering from what appears to be a contagious strain of avian flu, state media reported Friday. ... more info |
| Research on the H5N1 influenza (bird flu) virus' human transmissibility is seriously starting to worry WHO (World Health Organization) experts - in a written statement, the authors express concern about the potential risks linked to this research. The possible negative consequences of some experiments are serious and potentially dangerous... ... more info |
| Research on the H5N1 influenza (bird flu) virus' human transmissibility is seriously starting to worry WHO (World Health Organization) experts - in a written statement, the authors express concern about the potential risks linked to this research. The possible negative consequences of some experiments are serious and potentially dangerous... ... more info |
The culling is part of a series of precautionary steps being taken after the chicken carcass was found to have a “highly pathogenic H5N1 avian influenza virus,” officials said.
... more info |
The culling is part of a series of precautionary steps being taken after the chicken carcass was found to have a “highly pathogenic H5N1 avian influenza virus,” officials said.
... more info |
| The Hong Kong government said Wednesday that more than 17,000 chickens were being culled at a poultry market after a chicken carcass tested positive for avian flu. ... more info |
| Imagine this, our worst nightmare becomes our reality: as anticipated, the deadly H5N1 bird flu virus that kills most people it infects has acquired the ability to transmit easily from bird to human and then from human to human and has reached pandemic proportions... ... more info |
| Imagine this, our worst nightmare becomes our reality: as anticipated, the deadly H5N1 bird flu virus that kills most people it infects has acquired the ability to transmit easily from bird to human and then from human to human and has reached pandemic proportions... ... more info |
An educator from the Scandinavian country that ranks among the world’s leaders in school quality visited New York and explained his nation’s success.
... more info |
| During the 1918 to 1920 global influenza epidemic, between 50 to 100 million people lost their lives, with over a quarter of the world's population having being infected. Although vaccines might help in the event of a similar outbreak today, the possibility still remains that vaccine production would not be able to cope with such an influx in demand to make an important impact... ... more info |
| Flu season is upon us and while getting the nasty bug is bad news, the good news is it's now possible to treat the severe form of the virus more effectively, according to a Ryerson University researcher. Though Canada is not expecting a pandemic flu season this winter Health Canada reports that about 4,000 to 8,000 Canadians die each year from flu-related pneumonia... ... more info |
| A study published in the online journal mBio on November 29 shows that adding antibiotics to swine feed causes microorganisms in the guts of these animals to start sharing genes that could spread antibiotic resistance. Livestock farms use antibiotic drugs regularly, and not just for curing sick animals... ... more info |
| Annual Childhood Flu Vaccines May Interfere With Development of Crossresistance Vaccinating children annually against influenza virus interferes with their development of cross-reactive killer T cells to flu viruses generally, according to a paper in the November Journal of Virology... ... more info |
| Researchers conducting influenza-like illness surveillance in Cambodia have confirmed a rare incidence of individuals becoming infected with a seasonal influenza and the pandemic strain at the same time, a reminder of the ongoing risk of distinct flu viruses combining in human hosts to produce a more lethal strain, according to a report in the November issue of the American Jou... ... more info |
|
| The Canadian Food Inspection Agency (CFIA) has confirmed that the virus detected in a commercial poultry operation in the Rural Municipality of Rockwood, Manitoba is low pathogenic H5N2 avian influenza. Pathogenicity refers to the severity of the illness caused in birds. The infected farm remains under quarantine, and all birds in the operation will be humanely destroyed within days... ... more info |
| The Canadian Food Inspection Agency (CFIA) has confirmed the presence of an avian influenza virus in a commercial poultry operation in the Rural Municipality of Rockwood, Manitoba. Further testing is underway to determine the precise subtype and pathogenicity of the virus. Pathogenicity refers to the severity of the illness caused in birds... ... more info |
|
| Bird Flu Case In Hong Kong Isolated Health officials in Hong Kong confirmed on Monday that the woman diagnosed with H5N1 (bird) flu after a trip to China this month is now in stable condition and did not contract a new strain of the virus, SAPA/DPA/Mail & Guardian report... ... more info |
| Hong Kong has confirmed that a 59-year old woman who recently travelled to mainland China has bird flu, the first human case in the special administrative region in seven years. Hong Kong had the world's first major bird flu outbreak in humans in 1997, where it killed six people, infected 12 others, and resulted in the culling of millions of birds... ... more info |
|
| Vaccination against Haemophilus influenzae type b, or Hib, once the most common cause of bacterial meningitis in children, has dramatically reduced the incidence of Hib disease in young children over the past 20 years, according to a study published in Clinical Infectious Diseases and available online... ... more info |
| A natural lipid in the fluid lining the lungs inhibits influenza infections in both cell cultures and mouse models, according to researchers at National Jewish Health. These findings, combined with previous studies demonstrating effectiveness against respiratory syncytial virus, suggest that the molecule, known as POPG, may have broad antiviral activity... ... more info |
| Muslims in Switzerland are responding with shock and outrage after a pig carcass and severed swine heads were discovered buried at the site of a proposed mosque. ... more info |
|
| Vaccination against Haemophilus influenzae type b, or Hib, once the most common cause of bacterial meningitis in children, has dramatically reduced the incidence of Hib disease in young children over the past 20 years, according to a study published in Clinical Infectious Diseases and available online... ... more info |
| A natural lipid in the fluid lining the lungs inhibits influenza infections in both cell cultures and mouse models, according to researchers at National Jewish Health. These findings, combined with previous studies demonstrating effectiveness against respiratory syncytial virus, suggest that the molecule, known as POPG, may have broad antiviral activity... ... more info |
| Researchers conducting influenza-like illness surveillance in Cambodia have confirmed a rare incidence of individuals becoming infected with a seasonal influenza and the pandemic strain at the same time, a reminder of the ongoing risk of distinct flu viruses combining in human hosts to produce a more lethal strain, according to a report in the November issue of the American Jou... ... more info |
|
| With cold and flu season almost here, the next time you're sick, think twice before taking something for your fever. That's because scientists have found more evidence that elevated body temperature helps certain types of immune cells to work better. This research is reported in the November 2011 issue of the Journal of Leukocyte Biology... ... more info |
|
| The Canadian Food Inspection Agency (CFIA) has confirmed that the virus detected in a commercial poultry operation in the Rural Municipality of Rockwood, Manitoba is low pathogenic H5N2 avian influenza. Pathogenicity refers to the severity of the illness caused in birds. The infected farm remains under quarantine, and all birds in the operation will be humanely destroyed within days... ... more info |
| The Canadian Food Inspection Agency (CFIA) has confirmed the presence of an avian influenza virus in a commercial poultry operation in the Rural Municipality of Rockwood, Manitoba. Further testing is underway to determine the precise subtype and pathogenicity of the virus. Pathogenicity refers to the severity of the illness caused in birds... ... more info |
|
| Bird Flu Case In Hong Kong Isolated Health officials in Hong Kong confirmed on Monday that the woman diagnosed with H5N1 (bird) flu after a trip to China this month is now in stable condition and did not contract a new strain of the virus, SAPA/DPA/Mail & Guardian report... ... more info |
| Hong Kong has confirmed that a 59-year old woman who recently travelled to mainland China has bird flu, the first human case in the special administrative region in seven years. Hong Kong had the world's first major bird flu outbreak in humans in 1997, where it killed six people, infected 12 others, and resulted in the culling of millions of birds... ... more info |
| Researchers who analyzed published literature found the type of flu shots used to inoculate 90% of Americans would only protect about 59% of the population, which is in stark contrast to established estimates of 70-90% effectiveness when there is a good match of vaccine to circulating strains... ... more info |
| What do gas pump handles, ATM buttons, mailbox handles and escalator rails have in common in the USA? As the flu season approaches, you may wish make a note of this: they are amongst the most germ-ridden and dirtiest surfaces that Americans touch every day, according to tests carried out in six US major cities recently... ... more info |
| The immune response to an H5N1 avian influenza vaccine was greatly enhanced in healthy adults if they were first primed with a DNA vaccine expressing a gene for a key H5N1 protein, researchers say. Their report describes results from two clinical studies conducted by researchers from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health... ... more info |
|
| A study published in the Journal of Infectious Diseases indicates that treatment with oseltamivir significantly reduces mortality in patients with influenza A/H5N1, or 'bird flu', even when given late in the course of illness. In humans, influenza A/H5N1 is associated with severe disease and a high mortality rate... ... more info |
|
| On the eve of the 2010-11 influenza flu season, scientists and engineers have identified the environmental conditions and surfaces that could enable a highly pathogenic (H5N1) bird flu virus to survive for prolonged periods of time - at least two weeks and up to two months. Among them: The virus appears to thrive at cooler temperatures and low humidity... ... more info |
| In this week's PLoS Medicine, Joseph Wu of the University of Hong Kong, Hong Kong and colleagues report that using serological data coupled with clinical surveillance data can provide real-time estimates of the infection attack rates and severity in an emerging influenza pandemic... ... more info |
| Researchers at Rutgers and UMDNJ-Robert Wood Johnson Medical School have determined the structure of a protein that is the first line of defense in fighting viral infections including influenza, hepatitis C, West Nile, rabies, and measles... ... more info |
Tomas Transtromer is acclaimed as one of the most important Scandinavian writers since World War II.
... more info |
| In this week's PLoS Medicine, Joseph Wu of the University of Hong Kong, Hong Kong and colleagues report that using serological data coupled with clinical surveillance data can provide real-time estimates of the infection attack rates and severity in an emerging influenza pandemic... ... more info |
| The immune response to an H5N1 avian influenza vaccine was greatly enhanced in healthy adults if they were first primed with a DNA vaccine expressing a gene for a key H5N1 protein, researchers say. Their report describes results from two clinical studies conducted by researchers from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health... ... more info |
| Researchers at Rutgers and UMDNJ-Robert Wood Johnson Medical School have determined the structure of a protein that is the first line of defense in fighting viral infections including influenza, hepatitis C, West Nile, rabies, and measles... ... more info |
|
| A study published in the Journal of Infectious Diseases indicates that treatment with oseltamivir significantly reduces mortality in patients with influenza A/H5N1, or 'bird flu', even when given late in the course of illness. In humans, influenza A/H5N1 is associated with severe disease and a high mortality rate... ... more info |
|
| On the eve of the 2010-11 influenza flu season, scientists and engineers have identified the environmental conditions and surfaces that could enable a highly pathogenic (H5N1) bird flu virus to survive for prolonged periods of time - at least two weeks and up to two months. Among them: The virus appears to thrive at cooler temperatures and low humidity... ... more info |
|
| Many viruses infecting humans including influenza virus, hepatitis C virus, West Nile virus, rabies and measles viruses contain a ribonucleic acid (RNA) genome. These viruses are dependent on RNA as genetic information and they duplicate in human cells to make copies, thereby infecting other cells and spreading the virus... ... more info |
| Fresh insight into how viruses such as SARS and flu can jump from one species to another may help scientists predict the emergence of diseases in future. Researchers have shown that viruses are better able to infect species that are closely related to their typical target species than species that are distantly related... ... more info |
| An H5 bird flu (avian flu) outbreak in West Bengal, eastern India has triggered the culling of poultry and eggs, authorities have informed. Infected birds have been reported in the Nadia district of West Bengal, according to India's Ministry of Agriculture. A mutant bird flu strain is spreading in other parts of Asia... ... more info |
|
| Many of the people who died from the new strain of H1N1 influenza that broke out in 2009 were suffering from another infection as well: pneumonia. A new study published today, September 20 in the online journal mBio reveals how the two infections, pandemic influenza and pneumonia, interact to make a lethal combination... ... more info |
| Queen's University medical researchers have released some key findings from the first study of its kind done in Canada on the impact of colds and flu on school absenteeism, the workplace, and the economy. The researchers reviewed more than 80 published clinical trials, studies and research projects representing the work of over 300 researchers from more than 100 universities and institutions... ... more info |
|
| Immunization, Including Flu Vaccine, Can Thwart Pneumonia in Children, Guidelines Suggest Immunizations, including a yearly flu vaccine, are the best way to protect children from life-threatening pneumonia, according to new guidelines from the Pediatric Infectious Diseases Society (PIDS) and the Infectious Diseases Society of America (IDSA) -- Current treatment and... ... more info |
| The US Centers for Disease Control and Prevention (CDC) have made a startling announcement this week. Two children previously vaccinated for the H1N1 influenza virus have contracted a new strain named H3N2 in what is being called a virus "reassortment... ... more info |
|
| NexBio, Inc. announced publication of "Treatment of Parainfluenza 3 Infection with DAS181 in a Patient after Allogeneic Stem Cell Transplantation" in the Journal Clinical Infectious Diseases. The lead author, Dr. Yi-Bin Chen, of the Department of Medicine, Massachusetts General Hospital and Harvard Medical School, is the treating physician for the first of these patients... ... more info |
| EUREKA project E! 4104 ECOPROMAT has developed a novel and environmentally-friendly type of matting for use in protection against the spread of contagious animal diseases such as avian influenza, and for routine hygiene in animal and food production. Soaked with disinfectant solution, the matting can be used for disinfecting vehicle tyres, and the shoes and boots of personnel... ... more info |
|
| Novartis announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Aflunov, an investigational pre-pandemic avian influenza vaccine. The CHMP is endorsing the approval of Aflunov for active immunization against H5N1 subtype of Influenza A virus in adults 18 years of age and older... ... more info |
The Food and Agriculture Organization of the United Nations warned of “a possible major resurgence” of the H5N1 highly pathogenic avian influenza virus in the coming months.
... more info |
| The United Nations warned Monday of a possible resurgence of the deadly avian flu virus, saying there are indications a mutant strain may be spreading in Asia. ... more info |
|
| The possibility of a major resurgence of Highly Pathogenic Avian Influenza H5N1 - also known as bird flu - has prompted the United Nation's FAO (Food and Agriculture Organization) to advise health authorities around the world to step up surveillance and readiness. There are signs that a mutant strain of Bird Flu is making inroads in Asia and other parts of the world... ... more info |
| That micro-organisms have a great capacity to vary their surface structure is well known. It is one of the reasons why it is so difficult to develop vaccines against HIV and malaria, and why new influenza vaccines have to be produced every year. But it seems that these micro-organisms are also able to completely avoid activating a strong immune response in the person attacked... ... more info |
| That micro-organisms have a great capacity to vary their surface structure is well known. It is one of the reasons why it is so difficult to develop vaccines against HIV and malaria, and why new influenza vaccines have to be produced every year. But it seems that these micro-organisms are also able to completely avoid activating a strong immune response in the person attacked... ... more info |
|
| MIT scientists have designed a new medication that can identify cells that have been infected by a virus, any type of virus, then destroy those cells and effectively end the infection. The researchers, from MIT's Lincoln Laboratory, published their breakthrough in the journal PLoS One. This new technology has the potential to eventually cure the common cold, the flu and several other illnesses... ... more info |
|
| Most bacterial infections can be treated with antibiotics such as penicillin, discovered decades ago. However, such drugs are useless against viral infections, including influenza, the common cold, and deadly hemorrhagic fevers such as Ebola... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
|
| Avian influenza virus is a threat to the commercial chicken industry and, with its recent rapid spread across China, has also shown the ability for transmission from chickens to humans and other mammals. In an article in Journal of Interferon & Cytokine Research, a peer-reviewed journal published by Mary Ann Liebert, Inc... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
| A new University of Maryland-led study finds that 'sex' between the virus responsible for the 2009 flu pandemic (H1N1) and a common type of avian flu virus (H9N2) can produce offspring - new combined flu viruses - with the potential for creating a new influenza pandemic... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
|
| Influenza viruses spread quickly, are quite common and can have devastating consequences. Thus, drugs that help restrict the spread of influenza not only shorten the sickness, but save lives... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
|
| Influenza viruses spread quickly, are quite common and can have devastating consequences. Thus, drugs that help restrict the spread of influenza not only shorten the sickness, but save lives... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
|
| Novartis announced today that the Company has started shipping seasonal influenza vaccine to its US customers for the 2011-2012 influenza season. Early delivery of seasonal influenza vaccine will ensure healthcare professionals have the ability to provide the earliest possible protection against influenza... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
| A new University of Maryland-led study finds that 'sex' between the virus responsible for the 2009 flu pandemic (H1N1) and a common type of avian flu virus (H9N2) can produce offspring - new combined flu viruses - with the potential for creating a new influenza pandemic... ... more info |
|
| Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon™ DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation... ... more info |
| Annually changing flu vaccines with their hit-and-miss effectiveness may soon give way to a single, near-universal flu vaccine, according to a new report from scientists at The Scripps Research Institute and the Dutch biopharmaceutical company Crucell... ... more info |
|
| Viruses are the most abundant parasites on Earth. Well known viruses, such as the flu virus, attack human hosts, while viruses such as the tobacco mosaic virus infect plant hosts. More common, but less understood, are cases of viruses infecting bacteria known as bacteriophages, or phages... ... more info |
|
| Americans 65 years of age and older are at the highest risk of developing severe complications from influenza, but these same individuals receive less protection from annual influenza vaccination than others... ... more info |
|
| Dr Seizaburo Kashiwagi presented the preliminary data from an influenza Phase III prophylaxis study conducted during the 2009/2010 pandemic flu season in Japan. The SHIELD study (Study of Household Influenza prophylaxis Effect of Long-acting anti-influenza Drug) presentation was made at the 59th Annual Meeting of the Japanese Society of Chemotherapy... ... more info |
| There is a case for universal vaccination of children aged six months to five years with the seasonal flu jab, suggest Professor David Mant and colleague Consultant Epidemiologist Richard Mayon-White, in an editorial1 in this month's British Journal of General Practice (BJGP)... ... more info |
|
| In 2005 the bird or avian flu was no joke. Charles Hensley, however, has been arrested for pushing medications in 2005 and marketing the illegal drug Vira 38, not approved by the FDA or in Hong Kong for that matter, which was supposedly able to prevent symptoms of the deadly outbreak that gripped the globe. Hensley has pleaded not guilty... ... more info |
| An evaluation of the Public Health Grid (PHGrid) technology during the 2009 H1N1 influenza pandemic could enhance the capabilities of epidemiologists and disease-control agencies when the next emergent disease appears, according to a study published in the International Journal of Grid and Utility Computing... ... more info |
|
| In 2005 the bird or avian flu was no joke. Charles Hensley, however, has been arrested for pushing medications in 2005 and marketing the illegal drug Vira 38, not approved by the FDA or in Hong Kong for that matter, which was supposedly able to prevent symptoms of the deadly outbreak that gripped the globe. Hensley has pleaded not guilty... ... more info |
| Using a combination of sophisticated modelling and statistical analyses, David Fisman and colleagues show that infection with influenza likely increases the incidence of invasive pneumococcal disease (IPD)... ... more info |
|
| NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company") announced today that it has been invited to present its anti-influenza drug development studies at the TechConnect World 2011 Conferences and Expo. The Conferences and Expo are being held June 13-16 at the Hynes Convention Center in Boston, MA. Dr. Anil R... ... more info |
|
| In 2005 the bird or avian flu was no joke. Charles Hensley, however, has been arrested for pushing medications in 2005 and marketing the illegal drug Vira 38, not approved by the FDA or in Hong Kong for that matter, which was supposedly able to prevent symptoms of the deadly outbreak that gripped the globe. Hensley has pleaded not guilty... ... more info |
|
| Fraunhofer USA Center for Molecular Biotechnology (CMB), a not-for-profit, Delaware-based organization focused on developing a proprietary plant-based protein production platform and its applications in vaccine and therapeutic fields, today announced positive interim results from the first human trial of plant-produced H1N1 influenza vaccine (HAC1) that began on September 13, 2010... ... more info |
|
| CEL-SCI Corporation (NYSE Amex: CVM) today announced the positive results of efficacy studies in mice of L.E.A.P.S.TM (Ligand Epitope Antigen Presentation System) H1N1 activated dendritic cells (DCs) to treat the H1N1 virus. Scientists found that H1N1-infected mice treated with LEAPS-H1N1 DCs showed a survival advantage over mice treated with control DCs... ... more info |
| Young and middle aged adults bore the brunt of influenza this winter with more than 70 per cent of fatal cases hitting this age group, according to figures published by the Health Protection Agency (HPA) in their annual flu report today (Wednesday)... ... more info |
| Gerardo Chowell and coworkers report the incidence of pandemic influenza H1N1 morbidity and mortality in 32 Mexican states in 2009 and quantify the association between local influenza transmission rates, school cycles, and demographic factors... ... more info |
| Sepsis is the name of an infection that causes a series of reactions in the body, which in the worst case can prove fatal. The problem for both patients and doctors is that the early symptoms are difficult to distinguish from less dangerous infections such as a severe flu or winter vomiting disease... ... more info |
|
| New research shows that African Americans with systemic lupus erythematosus (SLE) had a higher antibody response to influenza vaccination than European American patients... ... more info |
|
| The research-based pharmaceutical industry, represented by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), welcomes the assessment of the global response to the 2009 H1N1 pandemic conducted by the independent International Health Regulations (IHR) Review Committee, whose final report was the subject of a resolution[1] approved by the World Health Assembly... ... more info |
|
| New research shows that African Americans with systemic lupus erythematosus (SLE) had a higher antibody response to influenza vaccination than European American patients... ... more info |
|
| It is important for health care providers to report health issues, such as influenza outbreaks, to public health authorities. But there is evidence of a reluctance to share patient data for public health purposes due to concerns for both patient privacy and provider confidentiality. Dr... ... more info |
|
| The development of new vaccines and drugs to combat the flu could be accelerated thanks to a new testing system. Collaboration between MSD and Deakin University's professor of public health, Richard Osborne, has resulted in the development of a new way to understand the intensity and impact of the flu that will enable scientists to better assess if new treatments work... ... more info |
|
| A research article May 12 in Science demonstrates the use of computational methods to design new antiviral proteins not found in nature, but capable of targeting specific surfaces of flu virus molecules. One goal of such protein design would be to block molecular mechanisms involved in cell invasion and virus reproduction... ... more info |
| The Centers for Medicare & Medicaid Services (CMS) today proposed new requirements for Medicare-certified providers that are designed to expand access to seasonal influenza vaccination... ... more info |
|
| The persistence and recurrence of H5N1 avian influenza in endemic regions can largely be blamed on movement and infection by migratory birds. Trade in poultry, poultry products and caged birds, and movement of wild birds also account for H5N1 prevalence in these areas... ... more info |
|
| 17 April 2011 -- After a week of negotiations continued through Friday night and into Saturday morning, an open-ended working-group meeting of Member States successfully agreed upon a framework to ensure that in a pandemic, influenza virus samples will be shared with partners who need the information to take steps to protect public health. ... more info |
| The nation's feral pig population continues to expand, increasing the potential for interaction with humans and domestic swine - and for spreading diseases. Researchers at North Carolina State University examined feral pigs from eastern North Carolina to determine exposure to two parasites that can be transmitted from animals to people - Toxoplasma gondii (T. gondii) and Trichinella... ... more info |
| New research on mice has shown that pulmonary administration of granulocyte macrophage-colony stimulating factor (GM-CSF) significantly reduces flu symptoms and prevents death after a lethal dose influenza virus... ... more info |
|
| After a week of negotiations continued through Friday night and into Saturday morning, an open-ended working-group meeting of Member States successfully agreed upon a framework to ensure that in a pandemic, influenza virus samples will be shared with partners who need the information to take steps to protect public health... ... more info |
|
| The Duke Human Vaccine Institute has announced a collaboration and strategic agreement with Novartis Vaccines and Diagnostics to enable the rapid development of a vaccine and accelerate preparedness in case of a pandemic virus threat such as pandemic influenza... ... more info |
|
| New research from Phoenix Healthcare measuring influenza vaccine purchasing dynamics highlights increased competition among suppliers and distributors of the vaccine. As a result, physician practices are welcoming the opportunity to capitalize by improving their financial return on flu vaccine administration... ... more info |
|
| The persistence and recurrence of H5N1 avian influenza in endemic regions can largely be blamed on movement and infection by migratory birds. Trade in poultry, poultry products and caged birds, and movement of wild birds also account for H5N1 prevalence in these areas... ... more info |
| A contract has been awarded to develop a long-acting single-dose antiviral drug for use in the United States, the U.S. Biomedical Advanced Research and Development Authority (BARDA) announced today. The drug, CS-8958, is currently marketed in Japan under the name Inavir and is in the same class of drugs as the currently approved influenza antiviral drugs Tamiflu and Relenza... ... more info |
| Evolva Holding SA (SIX: EVE) today announced that the US Food and Drug Administration (FDA) has cleared Evolva's request to test EV-077 in man, under an Investigational New Drug (IND) application for influenza. Neil Goldsmith, CEO and Managing Director of Evolva commented: "This regulatory clearance by the FDA is an important milestone in the development of EV-077... ... more info |
| Evolva Holding SA (SIX: EVE) today announced that the US Food and Drug Administration (FDA) has cleared Evolva's request to test EV-077 in man, under an Investigational New Drug (IND) application for influenza. Neil Goldsmith, CEO and Managing Director of Evolva commented: "This regulatory clearance by the FDA is an important milestone in the development of EV-077... ... more info |
| A series of six one-hour video lectures featuring Georgia Health Sciences University faculty are helping educate the public, including primary care physicians statewide, about seasonal and pandemic flu. The videos, funded by the Georgia Division of Public Health, cover a wide range of topics - from basics of pandemic flu to triage protocols... ... more info |
| It would take just a small change in DNA to create a mutation of the 2009 H1N1 "swine flu" virus that could spread more easily, concluded US scientists in a recent PLoS ONE paper where they also showed that their method could be used to monitor the evolution of H1N1, particularly that part of its DNA that determines how well the virus binds to the respiratory tract ... ... more info |
|
| Existing plans for antiviral and antibiotic use during a severe influenza pandemic could reduce wastewater treatment efficiency prior to discharge into receiving rivers, resulting in water quality deterioration at drinking water abstraction points... ... more info |
| Ever get a flu shot and still get the flu? If so, there's new hope for flu-free winters in the years to come thanks to a new discovery by researchers who found that a drug called DMXAA, originally developed as anti-tumor agent, enhances the ability of flu vaccines to ward off this deadly virus... ... more info |
| A stockpiled vaccine designed to fight a strain of avian flu that circulated in 2004 can be combined with a vaccine that matches the current strain of bird flu to protect against a potential pandemic, researchers from Saint Louis University's Center for Vaccine Development have found... ... more info |
| Adelaide researchers have taken a step closer to the development of a universal flu vaccine, with results of a recent study showing that a vaccine delivered by a simple nasal spray could provide protection against influenza. University of Adelaide researcher Dr Darren Miller and colleagues have successfully trialled a synthetic universal flu vaccine in mice... ... more info |
| Between 3,000 to 3,500 anti-government protesters demonstrated peacefully in the Yemeni capital Sanaa for the 11th consecutive day Monday. ... more info |
| A stockpiled vaccine designed to fight a strain of avian flu that circulated in 2004 can be combined with a vaccine that matches the current strain of bird flu to protect against a potential pandemic, researchers from Saint Louis University's Center for Vaccine Development have found... ... more info |
|
| Baxter International Inc. announced results of a study published in this week's issue of The Lancet that demonstrate effectiveness and tolerability of Baxter's PREFLUCEL in protecting against seasonal influenza. The study data show nearly 80 percent protective efficacy against the influenza strains contained in the vaccine and a low adverse event profile... ... more info |
| A stockpiled vaccine designed to fight a strain of avian flu that circulated in 2004 can be combined with a vaccine that matches the current strain of bird flu to protect against a potential pandemic, researchers from Saint Louis University's Center for Vaccine Development have found... ... more info |
| |
|
